Evidence map›Paper›PMID 34053790›Full record

ArticleVaccine2021

Protein and glycan molecular weight determination of highly glycosylated HIV-1 envelope trimers by HPSEC-MALS.

Michael F Bender, Yile Li, Vera B Ivleva, Daniel B Gowetski, Q Paula Lei

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Characterization of a SARS-CoV-2 spike protein reference material.Analytical and bioanalytical chemistry · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Michael F BenderVaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, United States.
Yile LiVaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, United States.
Vera B IvlevaVaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, United States.
Daniel B GowetskiVaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, United States.
Q Paula LeiVaccine Production Program Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Disease, United States. Electronic address: paula.lei@nih.gov.
National Institute of Allergy and Infectious Diseases · USInstitut de Recherche Vaccinale · FR

Funding

Development and Production of HIV Vaccines and AdjuvantsZIBAI005154 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GALL, JASON · 2020 to 2025
$56.7M
Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

High Performance Size-Exclusion Chromatography coupled with Multi-Angle Light Scattering detection (HPSEC-MALS) is an important tool to provide a reliable molecular weight measurement for a large complex biomolecule. A recent HIV-1 soluble envelope trimer vaccine candidate, BG505 DS-SOSIP.664, is among the most glycosylated proteins to enter a clinical trial to date, and determination of its protein and glycan molecular weight is one of the key attributes in pre-clinical characterization. However, protein and glycans possess disparate dndcvalues making molecular weight measurement inaccurate in conventional SEC-MALS. To overcome these challenges, a simple mathematically guided experiment was explored, and a composite dndcvalue was established by utilizing protein and glycan mass contributions for the HIV-1 envelope trimer. This establishment was further verified by an orthogonal mass spectrometry analysis. This innovative, simple, and quick analytical approach can be applied broadly to measuring the molecular weight of various composite molecular structures, such as complex glycoconjugates.

Indexed as

HIV-1Antibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesMolecular WeightPolysaccharidesProtein MultimerizationAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency VirusHIV AntibodiesPolysaccharidesGlycoproteinHIV-1Molecular WeightSEC-MALS

Identifiers

PMID34053790
PMCPMC11106716
OpenAlexW3164089304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.